03353nam 2200757 a 450 991045537660332120200520144314.01-282-23921-X97866122392120-309-12756-4(CKB)1000000000787842(EBL)3378501(SSID)ssj0000097023(PQKBManifestationID)11138048(PQKBTitleCode)TC0000097023(PQKBWorkID)10081960(PQKB)10998782(MiAaPQ)EBC3378501(Au-PeEL)EBL3378501(CaPaEBR)ebr10315883(CaONFJC)MIL223921(OCoLC)923280395(EXLCZ)99100000000078784220091008d2009 uy 0engur|n|---|||||txtccrAcute exposure guideline levels for selected airborne chemicalsVolume 7[electronic resource] /Committee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies, National Research Council of the National AcademiesWashington, D.C. National Academies Press20091 online resource (251 p.)Acute exposure guideline levels for selected airborne chemicalsDescription based upon print version of record.0-309-12755-6 Includes bibliographical references.""Preface""; ""Contents""; ""National Research Council Committee Review of Acute Exposure Guideline Levels for Selected Airborne Chemicals""; ""Roster of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances""; ""1 Acetone Cyanohydrin""; ""APPENDIX A DERIVATION OF AEGL VALUES FOR ACETONE CYANOHYDRIN""; ""2 Carbon Disulfide""; ""APPENDIX B ACUTE EXPOSURE GUIDELINES FOR CARBON DISULFIDE""; ""3 Monochloroacetic Acid""; ""APPENDIX A TIME-SCALING CALCULATIONS FOR AEGLS""; ""4 Phenol""; ""APPENDIX C ACUTE EXPOSURE GUIDELINES FOR PHENOL""Hazardous substancesEnvironmental aspectsHazardous substancesHealth aspectsPollutionEnvironmental aspectsPollutionPhysiological effectPollutionHealth aspectsChemicalsPhysiological effectChemicalsHealth aspectsAir quality managementToxicologyElectronic books.Hazardous substancesEnvironmental aspects.Hazardous substancesHealth aspects.PollutionEnvironmental aspects.PollutionPhysiological effect.PollutionHealth aspects.ChemicalsPhysiological effect.ChemicalsHealth aspects.Air quality management.Toxicology.615.9National Research Council (U.S.).Committee on Toxicology.National Research Council (U.S.).Board on Environmental Studies and Toxicology.MiAaPQMiAaPQMiAaPQBOOK9910455376603321Acute exposure guideline levels for selected airborne chemicals1914293UNINA05219nam 2200673Ia 450 99621829360331620240418063805.01-281-32099-497866113209970-470-75726-40-470-75724-8(CKB)1000000000402898(EBL)351209(OCoLC)437218497(SSID)ssj0000179344(PQKBManifestationID)11184086(PQKBTitleCode)TC0000179344(PQKBWorkID)10138003(PQKB)11138518(MiAaPQ)EBC351209(Au-PeEL)EBL351209(CaPaEBR)ebr10232599(CaONFJC)MIL132099(EXLCZ)99100000000040289820020103d2002 uy 0engur|n|---|||||txtccrInhibitors in patients with haemophilia[electronic resource] /edited by E.C. Rodriguez-Merchan, C.A. Lee1st ed.Osney Mead, Oxford ;Malden, MA Blackwell Sciencec20021 online resource (230 p.)Description based upon print version of record.0-632-06477-3 Includes bibliographical references and index.Inhibitors in Patients with Haemophilia; Contents; Contributors; Preface; Part 1: Haematology; 1 Natural history of inhibitors in severe haemophilia A and B: incidence and prevalence; 2 Characterization of inhibitors in congenital haemophilia; 3 Incidence and prevalence of inhibitors and type of blood product in haemophilia A; 4 Genetic basis of inhibitor development in severe haemophilia A and B; Part 2: Management of treatment; 5 Methods: plasmapheresis and protein A immunoadsorption; 6 Venous access in children with inhibitors; Part 3: Immune tolerance7 Immune tolerance: high-dose regimen8 Immune tolerance: low-dose regimen; 9 Immune tolerance and choice of concentrates; 10 Immune tolerance: The North American Immune Tolerance Registry; Part 4: Medical management of bleeding episodes; 11 The treatment of bleeding episodes in children; 12 General medical management of bleeding episodes: haemarthroses, muscle haematomas, mucocutaneous bleeding and haematuria; 13 Life- and limb-threatening episodes and intracranial bleeds; Part 5: Inhibitors in haemophilia B, inhibitors in mild and moderate haemophilia A and acquired inhibitors to FVIII14 Factor IX inhibitors and anaphylaxis15 Inhibitors in mild and moderate haemophilia A; 16 Acquired inhibitors to factor VIII; Part 6: Musculoskeletal issues; 17 Pathogenesis of musculoskeletal complications of haemophilia; 18 Orthopaedic management of haemarthroses; 19 Chemical synoviorthesis; 20 Radiosynoviorthesis in patients with haemophilia and inhibitors; 21 Musculoskeletal magnetic resonance imaging; 22 Treatment of iliopsoas haematomas and compartment syndromes in patients with haemophilia who have a circulating antibody23 A rational approach to the treatment of haemophilic blood cyst (pseudotumour) in patients with inhibitors24 Haemophilia patients with inhibitors: a rheumatologist's point of view; 25 Rehabilitation of patients with haemophilia and inhibitors; 26 Physiotherapy in the management of patients with inhibitors; 27 Elective orthopaedic surgery in haemophilia patients with high-responding inhibitors; Part 7: General surgery; 28 General and emergency surgery in patients with high-responding inhibitors; 29 Dental extraction in patients with haemophilia and inhibitors; Part 8: Psychosocial issues30 Psychosocial impact of inhibitors on haemophilia patients' quality of lifePart 9: General strategy for management of inhibitor patients; 31 General strategy for management of inhibitor patients (summary); 32 Immunoadsorption with anti-immunoglobulin antibodies using Ig-TheraSorb columns; 33 Standard, high and mega bolus doses of rVIIa or recombinant VIIa: comparison of three different treatment regimens; IndexEdited by an orthopaedic surgeon and a haematologist who are leading specialists in the treatment of haemophilia, Inhibitors in Patients with Haemophilia reviews the different haemostatic products and protocols for the control of bleeding and surgery in haemophilic patients with inhibitors. The book draws together in a single volume all of the clinical issues involved in the treatment of inhibitors from numerous specialists worldwide. It will be an invaluable resource for all those treating inhibitors in people with haemophilia.HemophiliaPathophysiologyHemophiliaTreatmentComplicationsHemophiliaImmunological aspectsHemophiliaPathophysiology.HemophiliaTreatmentComplications.HemophiliaImmunological aspects.616.1/572Rodriguez-Merchan E. C912313Lee Christine A912314MiAaPQMiAaPQMiAaPQBOOK996218293603316Inhibitors in patients with haemophilia2094839UNISA